N-803 + ETBX-071 + M-CENK
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High-risk Prostate Cancer
Conditions
High-risk Prostate Cancer
Trial Timeline
May 15, 2025 → Jun 30, 2031
NCT ID
NCT06765902About N-803 + ETBX-071 + M-CENK
N-803 + ETBX-071 + M-CENK is a phase 2 stage product being developed by ImmunityBio for High-risk Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06765902. Target conditions include High-risk Prostate Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06765902 | Phase 2 | Recruiting |
Competing Products
13 competing products in High-risk Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | GT Biopharma | Phase 1/2 | 33 |
| SHR3680 + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| DAPA/MET XR + DAPA + MET XR | AstraZeneca | Phase 3 | 77 |
| Pembrolizumab + BCG | Merck | Phase 3 | 77 |
| Blinatumomab + Investigator's Choice Chemotherapy + Dexamethasone | Amgen | Phase 2 | 51 |
| Blinatumomab | Amgen | Phase 2 | 51 |
| Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Etoposide + Rituximab + Doxorubicin + Vincristine + Prednisone | Gilead Sciences | Phase 3 | 76 |
| Darolutamide + ADT | Bayer | Phase 2 | 49 |
| Esmolol | Baxter | Phase 3 | 74 |
| N-803 (IL-15 Superagonist) + ETBX-071 (PSA-based Oncolytic Virus) + M-CENK (Activated NK Cells) | ImmunityBio | Phase 2 | 49 |
| Cretostimogene Grenadenorepvec | CG Oncology | Phase 2 | 49 |
| RP2 Injection | Replimune | Phase 2 | 44 |
| R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7 | PDS Biotechnology | Phase 1 | 25 |
Other Products from ImmunityBio
NAI + Pembrolizumab + NAI + Nivolumab + Ipilimumab + Pembrolizumab + NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice) + Cisplatin/carboplatin and pemetrexed plus pembrolizumab. + Cisplatin/carboplatin and pemetrexed plus atezolizumab. + Carboplatin and paclitaxel plus atezolizumab and bevacizumab. + Carboplatin and nab-paclitaxel plus atezolizumab. + NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxelPhase 3
74
N-803 + Tislelizumab + DocetaxelPhase 3
74
Aldoxorubicin + Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)Phase 3
74
N-803 and BCG + N-803Phase 2/3
62
hAd5-S-Fusion+N-ETSD + Placebo (0.9% (w/v) saline)Phase 2/3
62